Literature DB >> 27271159

Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort.

Jean-Paul Cervoni1, Àlex Amorós, Rafael Bañares, Jose Luis Montero, German Soriano, Delphine Weil, Richard Moreau, Marco Pavesi, Thierry Thévenot, Vincent Di Martino.   

Abstract

BACKGROUND/AIMS: The variations in C-reactive protein (CRP) levels have been reported to have prognostic significance in decompensated cirrhotic patients. We aimed to provide an external validation of a prognostic model combining model for end-stage liver disease (MELD) and 'sustained high CRP levels' as main variables and to optimize the model to the context of liver transplantation by focusing on 3-month mortality with no consideration of severe chronic extrahepatic diseases. PATIENTS AND METHODS: Data from cirrhotic patients enrolled in the CANONIC study were collected. Multivariate analyses used the competing risk model. The prognostic performance [area under receiver operating characteristic curve (AUROC)] of the model incorporating CRP variations within 15 days was compared with that of the MELD score alone.
RESULTS: 583 decompensated cirrhotic patients with Child-Pugh more than B7 and serial CRP measures available were included. Of these, 111 patients had baseline CRP at least 29 mg/l and 60 still had CRP at least 29 mg/l at day 15±6 (group A). Multivariate analysis (competing risk) identified three predictors of 3-month mortality: high MELD score [hazard ratio (HR)=1.14; 95% confidence intervals (CI): 1.11-1.17, P<0.001], age (HR=1.04; 95% CI: 1.02-1.06, P<0.001), and group A (HR=1.69; 95% CI: 1.01-2.81, P=0.046). The performance of the three variables taken together for predicting 3-month mortality was 0.796 (AUROC), which was significantly higher than that of the MELD score (AUROC=0.769; P=0.019).
CONCLUSION: In Child-Pugh higher than B7 cirrhotic patients with decompensation, prognostic models incorporating variations in CRP within 15 days and age predict 3-month mortality better than the MELD score alone. Such models would improve the ranking of candidates for liver transplantation by differentiating the severe patients with persistent systemic inflammation and intermediate MELD scores.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27271159     DOI: 10.1097/MEG.0000000000000676

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

1.  High Prevalence of Hormonal Changes and Hepatic Osteodystrophy in Frail Patients with Cirrhosis-An Observational Study.

Authors:  Surender Singh; Sunil Taneja; Puneeta Tandon; Arka De; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Radha Krishan Dhiman; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-11-26

2.  The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis.

Authors:  Theodora Oikonomou; Ioannis Goulis; Stefania Kiapidou; Nikoletta Tagkou; Evangelos Akriviadis; George Papatheodoridis; Evangelos Cholongitas
Journal:  Ann Gastroenterol       Date:  2020-09-16

3.  Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis.

Authors:  Maria Papp; Tamas Tornai; Zsuzsanna Vitalis; Istvan Tornai; David Tornai; Tamas Dinya; Andrea Sumegi; Peter Antal-Szalmas
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

Review 4.  Bacterial translocation markers in liver cirrhosis.

Authors:  Alexandra Alexopoulou; Danai Agiasotelli; Larisa E Vasilieva; Spyros P Dourakis
Journal:  Ann Gastroenterol       Date:  2017-07-25

5.  Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study.

Authors:  Nicolas Moreau; Xavier Wittebole; Yvan Fleury; Patrice Forget; Pierre-François Laterre; Diego Castanares-Zapatero
Journal:  Shock       Date:  2018-04       Impact factor: 3.454

6.  A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study.

Authors:  Florian Primavesi; Valentina Andreasi; Frederik J H Hoogwater; Stefano Partelli; Dominik Wiese; Charlotte Heidsma; Benno Cardini; Eckhard Klieser; Katharina Marsoner; Uwe Fröschl; Sabine Thalhammer; Ines Fischer; Georg Göbel; Andreas Hauer; Tobias Kiesslich; Philipp Ellmerer; Reinhold Klug; Daniel Neureiter; Helwig Wundsam; Franz Sellner; Peter Kornprat; Reinhold Függer; Dietmar Öfner; Elisabeth J M Nieveen van Dijkum; Detlef K Bartsch; Ruben H J de Kleine; Massimo Falconi; Stefan Stättner
Journal:  Cancers (Basel)       Date:  2020-05-14       Impact factor: 6.639

7.  Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial.

Authors:  Eva Román; Juan Camilo Nieto; Cristina Gely; Sílvia Vidal; Marta Pozuelo; Maria Poca; Cándido Juárez; Carlos Guarner; Chaysavanh Manichanh; Germán Soriano
Journal:  Hepatol Commun       Date:  2019-03-12

8.  The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis.

Authors:  Sana Khedher; Nasreddine Fouthaili; Amira Maoui; Sirine Lahiani; Mohamed Salem; Kahena Bouzid
Journal:  Gastroenterol Res Pract       Date:  2018-12-30       Impact factor: 2.260

9.  von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.

Authors:  Ziyuan Zou; Xinwen Yan; Cheng Li; Xiaofeng Li; Xiaofen Ma; Chunqing Zhang; Shenghong Ju; Junzhang Tian; Xiaolong Qi
Journal:  BMJ Open       Date:  2019-08-30       Impact factor: 2.692

10.  Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis.

Authors:  Vanessa Stadlbauer; Irina Komarova; Ingeborg Klymiuk; Marija Durdevic; Alexander Reisinger; Andreas Blesl; Florian Rainer; Angela Horvath
Journal:  Liver Int       Date:  2020-01-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.